There is strong evidence that epidermal growth factor receptor (EGFR) plays a role in tumor progression. A new study by Spano et al. has examined the relationship between EGFR expression ...
Research and Development Expenses: Research and development expenses were $15.9 million for the third quarter of 2024, compared to $6.9 million for the third quarter of 2023. The increase was ...
Dizal seeks US FDA approval for sunvozertinib to treat relapsed or refractory NSCLC with EGFR Exon 20 insertion mutations: Shanghai, China Saturday, November 9, 2024, 17:00 Hrs [I ...